Skip to content

PRESS RELEASES


PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Integra LifeSciences Announces Preliminary Fourth Quarter 2017 Financial Results
Preliminary Fourth Quarter Highlights: Fourth quarter 2017 reported revenue is expected to be approximately $365 million, exceeding the high-end of the company's previous implied guidance range of $345 million to $355 million; Organic revenue growth in the fourth quarter is expected to be about
View HTML
Toggle Summary Integra LifeSciences to Present at the 36th Annual J.P. Morgan Healthcare Conference
PLAINSBORO, N.J., Dec. 21, 2017 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced President and Chief Executive Officer Peter Arduini will speak at the 36 th Annual J.P.
View HTML
Toggle Summary Integra LifeSciences Hosts Investor Day 2017 New York City
PLAINSBORO, N.J., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today will host an Investor Day meeting with analysts and institutional investors in New York City, beginning at 8:00 a.m. EST.
View HTML
Toggle Summary Integra LifeSciences Reports Third Quarter 2017 Financial Results
Revenue Increased 11.4% to $279 million; Organic Revenue Increased 1.5%  Reported EPS of $0.04; Adjusted EPS of $0.45 PLAINSBORO, N.J., Oct. 26, 2017 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today reported financial
View HTML
Toggle Summary Integra LifeSciences to Host Third Quarter 2017 Earnings Results Conference Call on October 26, 2017
PLAINSBORO, N.J., Oct. 11, 2017 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, will release 2017 third quarter financial results on Thursday, October 26, 2017, prior to market open.
View HTML
Toggle Summary Integra LifeSciences launches Revize™/ Revize™-X Collagen Matrix for Plastic and Reconstructive Surgery
Revize and Revize-X are collagen matrices for plastic and reconstructive surgery, derived from fetal bovine dermis, available in solid and 2:1 meshed configurations
View HTML
Toggle Summary Integra LifeSciences launches SurgiMend® PRS Meshed Collagen Matrix for Plastic and Reconstructive Surgery
SurgiMend PRS Meshed is a collagen matrix for soft tissue reconstruction, featuring a 2:1 meshing pattern
View HTML
Toggle Summary Integra LifeSciences Launches Integra® SurgiMend™ PRS Meshed Collagen Matrix for Breast Reconstruction in Europe
Expands SurgiMend™ technology breast reconstruction product line
View HTML
Toggle Summary Integra LifeSciences Completes the Acquisition of Codman Neurosurgery Business from Johnson & Johnson
PLAINSBORO, N.J., Oct. 02, 2017 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART), a global leader in medical technology, announced today that it has completed the previously announced acquisition of the Johnson & Johnson Codman Neurosurgery business for approximately
View HTML
Toggle Summary Integra LifeSciences Provides Preliminary Assessment of Minor Damage to its Manufacturing Facility in Añasco, Puerto Rico
PLAINSBORO, N.J., Sept. 26, 2017 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced that its manufacturing facility in Añasco, Puerto Rico sustained relatively minor damage from the impact of Hurricane Maria.  A
View HTML
Toggle Summary Integra LifeSciences Announces First Patient Enrolled in Cadence® Total Ankle System Post-Market Study
PLAINSBORO, N.J., Sept. 21, 2017 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced the first Cadence ® Total Ankle System has been implanted by Dr. David Pedowitz with the Rothman Institute in Philadelphia,
View HTML
Toggle Summary Integra LifeSciences Announces Definitive Agreement to Sell Certain Neurosurgery Assets to Natus Medical Incorporated
Natus Medical to acquire global Camino® ICP monitoring product line, U.S. rights to Integra's fixed pressure shunts, and U.S. rights to Codman's DURAFORM®, EVD catheters and CSF collection systems Integra is providing a preliminary estimate for a fourth quarter 2017 revenue contribution of
View HTML
Toggle Summary Integra LifeSciences to Present at Healthcare Conferences in September 2017
PLAINSBORO, N.J., Aug. 17, 2017 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, will present at the Wells Fargo Healthcare Conference and the Morgan Stanley Healthcare Conference in September.
View HTML
Toggle Summary Integra's DuraSeal® dural sealant saves healthcare costs according to a study recently published in the Journal of Health Economics and Outcomes Research
Hospitals can reduce costs of cerebrospinal fluid (CSF) leaks after posterior fossa surgeries by using DuraSeal® instead of fibrin glue
View HTML
Toggle Summary Integra LifeSciences Reports Second Quarter 2017 Financial Results
Revenue Increased 13.2% to $282.2 million ; Organic Revenue Increased 4.6%  Reported EPS of $0.14 ; Adjusted EPS of $0.45, up 12.5% PLAINSBORO, N.J., July 26, 2017 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today
View HTML